Tag: GDP

Addressing Uncontrolled Hybrid Paper-Electronic Workflows in Validation Lifecycle In today’s pharmaceutical landscape, hybrid paper-electronic workflows present significant challenges, particularly in maintaining compliance during the validation lifecycle. As organizations strive for…

Addressing Weaknesses in System Access Controls During the Validation Lifecycle In the fast-paced pharmaceutical environment, compliance with 21 CFR Part 11 is critical. However, weaknesses in system access controls can…

A Comprehensive Playbook for Addressing Record Retention Failures in Pharmaceutical Systems Record retention failures pose significant challenges during system operation, especially in relation to compliance with 21 CFR Part 11.…

Addressing Weak System Access Controls During Upgrades to Prevent Part 11 Findings The pharmaceutical industry is continuously advancing, particularly with the integration of electronic recordkeeping systems. However, these upgrades can…

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system…

Strategies for Managing Record Retention Failures During System Upgrades In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of electronic records is paramount. Record retention failures during a system upgrade…

Managing ERES Controls Lapses During Compliance Audits: Your Playbook In an increasingly regulated environment, pharmaceutical manufacturers face mounting pressure to ensure robust compliance with Electronic Records and Electronic Signatures (ERES)…

Remediation for ERES Control Failures During System Operation In the evolving landscape of pharmaceutical manufacturing, the implementation of effective electronic records and electronic signatures (ERES) controls is critical. When ERES…

Strengthening System Access Controls During Upgrades: An Inspection-Ready Playbook Pharmaceutical manufacturers frequently confront challenges when upgrading electronic systems. A particularly critical issue arises when system access controls are weak during…

Handling Incomplete ERES Controls During Inspection Walkthroughs: A Comprehensive Playbook The pharmaceutical industry is under increasing scrutiny for the management of Electronic Records and Electronic Signatures (ERES). When ERES controls…

Risk-Based Remediation of ERES Controls Lapses During Inspection Walkthroughs In the pharmaceutical manufacturing realm, the integrity of electronic records and electronic signatures (ERES) is paramount. Encountering lapses in ERES controls…

Managing Hybrid Paper-Electronic Workflows: Tactics for Compliance During Inspections The increasing integration of hybrid paper-electronic workflows has created new challenges in regulatory compliance. Specifically, 21 CFR Part 11 requirements for…